Celgene's Michael Pehl leaps up to lead role at Immunomedics; GSK nabs Hal Barron to helm R&D; Aimmune CEO to step down
→ Michael Pehl will take the top job at Immunomedics next month after 11 years at Celgene, where he was most recently head of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
